Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA. Keywords. allergic bronchopulmonary aspergillosis; antifungal therapy; isavuconazole.
Allergic bronchopulmonary aspergillosis (ABPA) results from an abnormal exaggerated local and systemic immune response to conidia and hyphae colonizing the sinopulmonary tract. Allergic bronchopulmonary aspergillosis complicates asthma and cystic fibrosis in 1%-2% and 5%-15% of patients, respectively [1] . In asthmatic patients, ABPA presents as poorly controlled asthma with wheezing, cough, sputum production, low-grade fever, weight loss, and malaise.
Allergic bronchopulmonary aspergillosis management includes corticosteroids to control the host immune response and antifungal agents to decrease the burden of organism. Itraconazole is currently the first-line agent for symptomatic ABPA patients based on randomized, controlled clinical trials [2, 3] . Voriconazole is an alternative based on observational data [4] . However, both itraconazole and voriconazole are associated with significant adverse effects.
Isavuconazole is a broad-spectrum antifungal triazole with potent activity against Aspergillus species. It is recommended as an alternative primary therapy for invasive aspergillosis syndromes in the 2016 Infectious Diseases Society of America Guidelines [5] . We provide the first report of a patient with ABPA who was successfully treated with isavuconazole after having persistent symptoms and significant side effects with itraconazole and voriconazole.
METHODS
We first sought to understand the impact of systemic antifungal management on ABPA. We therefore systematically searched the PubMed database for English-language literature of antifungal therapy for ABPA in patients with underlying asthma. The following search terms were used: "itraconazole, " "voriconazole, " "posaconazole, " "isavuconazole, " "nebulized amphotericin B, " and "allergic bronchopulmonary aspergillosis. " We then report in detail our index case.
CASE REPORT
A 56-year-old female physician with asthma was seen in consultation in May 2015 for ABPA management. Her symptoms began in September 2009 when she developed a flu-like illness with fever, malaise, nonproductive cough, and decreased exercise tolerance. She regularly attended aerobic exercise classes, but she found that any activity that increased her respiratory rate lead to coughing "fits" that precluded further exercise.
In the spring of 2010, the cough and wheezing worsened, and she had new sputum production. A serum immunoglobulin (Ig)E level was 813 IU/mL, precipitating serum IgG antibodies to Aspergillus fumigatus were detected, Aspergillus skin testing was positive, and a sputum culture grew A fumigatus. A high-resolution computed tomography (CT) scan of the chest demonstrated mild hyperinflation of the lungs bilaterally and minimal inflammatory changes in the left mid-lung field. Pulmonary function tests (PFTs) revealed obstructive airways disease (forced expiratory volume [FEV] 1 2.08L, forced vital capacity [FVC] 3.02L, FEV 1 /FVC 69%) that did not improve after bronchodilator therapy. The patient was diagnosed with ABPA. In October 2010, she was prescribed prednisone 0.5 mg/ kg orally daily for 1 week followed by a taper over 3 months. Her respiratory symptoms improved such that she could participate in aerobic gym classes. The serum IgE decreased to 326 IU/mL. However, she was unable to discontinue corticosteroids entirely. Sputum cultures continued to grow Aspergillus species through July 2011. Pulmonary function tests showed stable mild obstruction.
Over the next year, her chronic cough and sputum production continued, and she lost 15 pounds unintentionally. She resumed prednisone at approximately 1 mg/kg in October 2011.
In December 2011, she started itraconazole; however, she developed hives, and the drug was discontinued. She was then treated with voriconazole 200 mg orally twice daily, and the cough and sputum production improved significantly. Prednisone was then tapered and discontinued. The serum IgE decreased from 663 IU/mL to 384 IU/mL. In March 2012, she stopped voriconazole due to an asymptomatic rise in the serum alanine aminotransferase (ALT) to 247 IU/L.
In fall 2012 and winter 2013, she had recurrent bronchitis and pneumonia due to Pseudomonas aeruginosa. A high-resolution CT scan of the chest showed cylindrical bronchiectasis in both lower lobes and bilateral, multiple, tiny lung nodules. Within the left lower lobe posterior basal segment, a 5.1 × 4.5 × 2.0 cm opacity was seen. Thick, white sputum was noted throughout the airways during bronchoscopy. Culture of bronchoalveolar lavage fluid grew Aspergillus species, Cladosporium species, and Stenotrophomonas maltophilia. Antifungal susceptibility data were not available. The patient resumed voriconazole in September 2014 and again had marked clinical improvement. The IgE levels decreased from 1583 IU/mL to 787 IU/mL. Pulmonary function tests showed moderate obstruction (FEV 1 1.61L, FEV 1 /FVC 68%). However, she experienced photopsia, and serum ALT increased to more than twice the upper limit of normal. Voriconazole was discontinued in March 2015. Given that the patient was not able to tolerate voriconazole and was concerned about the adverse effects of corticosteroids, she presented to New York-Presbyterian Hospital/Weill Cornell Medicine for further management.
Additional past medical history included corticosteroid-induced diabetes (diet-controlled), osteopenia, and seasonal allergies. Medications included N-acetylcysteine nebulizers, albuterol sulfate inhaler, azelastine-fluticasone nasal spray, beclomethasone inhaler, budesonide-formoterol inhaler, fexofenadine, and montelukast.
On physical examination, vital signs were unremarkable. The oxygen saturation was 96% while breathing ambient air. The body mass index was 17.4 kg/m 2 . Mid-inspiratory and expiratory wheezing was auscultated throughout the lung fields. The remainder of the exam was normal. Serum IgE level was 676 IU/mL. Erythrocyte sedimentation rate was 20 mm/hour (normal 0-40 mm/hour) and C-reactive protein was 0.5 mg/L (normal 0.0-4.9 mg/L). Given the patient's poor tolerance of corticosteroids (osteopenia and hyperglycemia), voriconazole (photopsia and elevated aspartate aminotransferase [AST] and ALT), and itraconazole (hypersensitivity reaction), she was prescribed oral isavuconazole 200 mg every 8 hours × 2 days, followed by 200 mg once daily. She was instructed to take isavuconazole in 4-month "pulses" so as to alleviate symptoms during ABPA exacerbations while reducing the risk of emergence of resistance. Over several weeks, she noted marked improvement in her sputum production and wheezing, and she was even able to backpack 16 miles in July 2015. She discontinued beclomethasone and continued on budesonide-formoterol alone. The serum IgE level remained elevated at 732 IU/mL. In August 2015, after 10 weeks of therapy, she stopped isavuconazole, noting that her Denning et al [12] Case exercise tolerance was the best it had been in years. She generally tolerated isavuconazole well, with the exception of watery diarrhea that she attributed to the drug and that lingered for several weeks after stopping therapy. The serum AST and ALT remained within normal limits. The patient continued to feel well throughout the fall 2015 and was maintained on budesonide-formoterol. On repeat PFTs, the FEV 1 had improved to 2.42L, and the FEV 1 /FVC was 68%. In January 2016, sputum production and wheezing increased, consistent with an ABPA exacerbation. The patient resumed isavuconazole in March 2016 with the same loading dose. Again she had marked symptomatic improvement, and she participated in 5 hiking trips during the spring and summertime. She stopped isavuconazole in May 2016. Pulmonary function tests were repeated in July 2016 and were within normal limits (FEV 1 2.43L, FVC 3.39L, FEV 1 /FVC 72%) ( Figure 1) . As of January 2017, she continues to have minimal respiratory symptoms, and she has remained off systemic corticosteroids and weaned inhaled corticosteroids to 1 puff of budesonide/formoterol daily.
REVIEW OF THE LITERATURE
We identified 3 randomized clinical trials and 16 observational studies (7 observational cohort studies, 1 case series, and 8 case reports) of itraconazole, voriconazole, posaconazole, and nebulized amphotericin B for the treatment of ABPA in patients with asthma (Table 1) .
DISCUSSION
To our knowledge, this is the first report of the use of isavuconazole for treatment of ABPA. Based on this patient's favorable clinical and physiologic response to isavuconazole, we believe that isavuconazole is a viable treatment option for patients with ABPA.
Isavuconazonium sulfate is a prodrug of the active triazole moiety, isavuconazole. Similar to other triazoles, isavuconazole prevents fungal cell membrane synthesis via inhibition of lanosterol-14α-demethylase. Isavuconazole has in vitro activity against many yeasts and moulds including Aspergillus species, Mucorales, Fusarium species, and dematiaceous molds.
Isavuconazole reduces fungal burden and improves clinical outcomes in experimental models of disseminated candidiasis and aspergillosis [6, 7] . In humans, a randomized, controlled clinical trial of patients with invasive aspergillosis and other filamentous fungal infections (SECURE trial) demonstrated that isavuconazole had comparable survival rates to that of voriconazole and was safer and better tolerated [8] . This trial, combined with preclinical data, led to the approval of isavuconazole for primary therapy of invasive aspergillosis in the United States and in Europe in 2015.
The patient reported herein tolerated isavuconazole well, had marked symptomatic improvement, and demonstrated a striking physiologic response in that her FEV 1 /FVC ratio normalized for the first time in 7 years after ABPA diagnosis. This impact on PFTs after taking isavuconazole suggests that it was more effective than voriconazole, although we cannot exclude the possibility that prior courses of voriconazole or improved asthma symptom management also contributed to the difference. Of note, isavuconazole also had a corticosteroid-sparing effect for the patient thus reducing the risk for short-term and long-term adverse effects. A potential explanation for the relatively greater response to treatment with isavuconazole versus voriconazole is that isavuconazole achieved higher drug exposure and a more rapid clearance of organism in comparison to voriconazole, for which therapeutic drug monitoring was not performed. An alternate explanation for subtherapeutic concentrations of voriconazole may be the phenomenon of autoinduction [9] . An advantage of isavuconazole is its predictable linear pharmacokinetics.
Treatment with isavuconazole is generally safe and well tolerated, a key distinguishing feature of the drug compared with other ABPA therapies. Unique adverse reactions among patients receiving voriconazole include transient vision changes, visual hallucinations, and photosensitivity [4] . Among patients on long-term therapy, periostitis and squamous cell carcinoma are concerns. Itraconazole is associated with gastrointestinal upset, congestive heart failure, rash, and increased liver enzymes. Posaconazole is associated with gastrointestinal upset depending on the formulation, and there are sparse data supporting its use for ABPA. Nebulized amphotericin B causes coughing and bronchospasm during inhalation [10] .
CONCLUSIONS
In summary, we present the first report of a patient with underlying asthma and ABPA to be successfully treated with isavuconazole with minimal adverse effects. Based on this case report, we suggest consideration of an open-label or randomized trial of isavuconazole versus voriconazole for the treatment of ABPA in patients with underlying asthma.
